BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29174859)

  • 1. Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
    Jiang F; Verma P
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):324-325. PubMed ID: 29174859
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
    Bruhn C
    Med Monatsschr Pharm; 2014 Jul; 37(7):268-9. PubMed ID: 25065170
    [No Abstract]   [Full Text] [Related]  

  • 3. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Robier C; Beham-Schmid C; Neubauer M
    Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    England JT; Leitch HA
    Leuk Lymphoma; 2018 Mar; 59(3):752-754. PubMed ID: 28728450
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib for Chronic Lymphocytic Leukemia.
    Ruchlemer R; Ben Ami R; Lachish T
    N Engl J Med; 2016 Apr; 374(16):1593-4. PubMed ID: 27096597
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib for Chronic Lymphocytic Leukemia.
    Rigolin GM; Cavazzini F; Cuneo A
    N Engl J Med; 2016 Apr; 374(16):1593. PubMed ID: 27096596
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibrutinib for Chronic Lymphocytic Leukemia.
    Sharman JP; Mato AR; Keating MJ
    N Engl J Med; 2016 Apr; 374(16):1592-3. PubMed ID: 27096595
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib for Chronic Lymphocytic Leukemia.
    Burger JA; Styles L; Kipps TJ
    N Engl J Med; 2016 Apr; 374(16):1594-5. PubMed ID: 27096594
    [No Abstract]   [Full Text] [Related]  

  • 9. Ibrutinib in relapsed chronic lymphocytic leukemia.
    Neffendorf JE; Gout I; Hildebrand GD
    N Engl J Med; 2013 Sep; 369(13):1277. PubMed ID: 24066759
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC; O'Brien S; James DF
    N Engl J Med; 2013 Sep; 369(13):1278-9. PubMed ID: 24066758
    [No Abstract]   [Full Text] [Related]  

  • 11. Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
    Harada K; Brooks JP; Lobo FM
    Ann Allergy Asthma Immunol; 2018 Nov; 121(5):629-630.e1. PubMed ID: 30009879
    [No Abstract]   [Full Text] [Related]  

  • 12. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
    Gaye E; Le Bot A; Talarmin JP; Le Calloch R; Belaz S; Dupont M; Tattevin P
    Med Mal Infect; 2018 Jun; 48(4):294-297. PubMed ID: 29402474
    [No Abstract]   [Full Text] [Related]  

  • 13. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
    Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
    [No Abstract]   [Full Text] [Related]  

  • 14. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
    Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
    Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
    Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
    Hillmen P; Diels J; Healy N; Iraqi W; Aschan J; Wildgust M
    Haematologica; 2018 May; 103(5):e204-e206. PubMed ID: 29419428
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia.
    Aronson FR
    Ann Intern Med; 2016 Apr; 164(8):JC44. PubMed ID: 27089094
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
    Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.